Kymera Therapeutics, Inc. balance sheet KYMR

Annual Quarterly

As of Sep 30, 2026, Kymera Therapeutics, Inc. had total assets of $1.8 billion and total liabilities of $152.7 million. Total assets were up 60.4% from a year earlier. Stockholders' equity was $1.6 billion. It held $1.6 billion in cash and investments against $76.6 million of total debt, net cash of $1.6 billion. The current ratio, current assets divided by current liabilities, was 11.13.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
Assets
Cash
373
+230.6%
357
+196.9%
120
+9.4%
110
+60.8%
68
+42.6%
48
+54.7%
31
Short-term investments
598
+52.2%
491
+33.3%
368
+39.1%
265
-21.8%
339
-14.1%
394
+48.7%
265
Long-term investments
675
+42.6%
771
+112.9%
362
+489.5%
61
-59.7%
152
+21.7%
125
-23.0%
163
Cash and investments
1,646
+68.2%
1,619
+90.3%
851
+95.0%
436
-22.0%
559
-1.4%
568
+23.7%
459
Receivables
—
—
0
-100.0%
15
—
—
—
Total current assets
999
+89.0%
871
+70.7%
510
+25.9%
405
-3.4%
419
-7.1%
451
+49.3%
302
Property and equipment, net
38
-15.3%
43
-14.4%
50
+4.8%
48
+261.0%
13
+12.2%
12
+9.6%
11
Total assets
1,767
+60.4%
1,743
+78.2%
978
+69.9%
576
-4.5%
603
-0.5%
606
+24.4%
487
Liabilities and equity
Accounts payable
12
+116.5%
4
-33.0%
6
-15.3%
7
+63.2%
4
+8.2%
4
-8.3%
4
Total current liabilities
90
+25.4%
83
+22.8%
68
-20.9%
86
+20.1%
71
-22.9%
93
-16.3%
111
Total liabilities
153
-2.0%
163
+14.6%
142
-21.2%
181
+60.0%
113
-22.8%
146
-28.0%
203
Stockholders' equity
1,615
+70.6%
1,580
+89.0%
836
+111.6%
395
-19.4%
490
+6.6%
460
+61.9%
284
Debt
Lease liabilities
77
-8.8%
82
-6.3%
88
+3.6%
85
+388.5%
17
-3.5%
18
-0.2%
18
Total debt
77
-8.8%
82
-6.3%
88
+3.6%
85
+388.5%
17
-3.5%
18
-0.2%
18
Net cash
1,569
+75.4%
1,537
+101.4%
763
+117.0%
352
-35.1%
542
-1.4%
550
+24.7%
441
Ratios
Current ratio
11.13x
10.47x
7.53x
4.73x
5.88x
4.88x
2.73x
Debt to equity
0.05x
0.05x
0.11x
0.21x
0.04x
0.04x
0.06x
Return on equity
-21.64%
-19.71%
-26.79%
-37.21%
-31.58%
-21.80%
-16.06%
Return on assets
-19.77%
-17.86%
-22.89%
-25.52%
-25.67%
-16.54%
-9.36%
Book value per share
18.92
19.42
12.88
—
8.91
8.92
6.38
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
KYMR (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Watertown, MA
SEC filer status
Large accelerated filer
SEC CIK
1815442
Former names
Kymera Therapeutics, Inc. (until Oct 29, 2026)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.